Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
Latest action · Oct 29, 2019 Received in the Senate and Read twice and referred to the Committee on Finance.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 8, 2019
- Passed HouseOct 28, 2019
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
This bill requires the Centers for Medicare & Medicaid Services (CMS) to publish certain payment information regarding pharmacy benefit managers (PBMs) and prescription drugs. Specifically, the CMS must publish certain information, as reported by PBMs, relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies, in accordance with specified confidentiality requirements.
The bill also provides statutory authority for certain provisions of the CMS rule titled "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," published on May 23, 2019. The rule requires, in part, Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that is capable of integrating with at least one prescriber's electronic prescribing system or electronic health record. The tool must provide prescribers with patient-specific, real-time formulary and benefit information, including information regarding cost-sharing, formulary alternatives, and utilization management requirements. The rule takes effect January 1, 2021.
Recorded votes 1
Newest first. Open one to see how every member voted.
Cosponsors 5
Members who signed on, in the order they did. Signatures ran from Apr 8, 2019 to Oct 28, 2019; 2 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-PA | Brendan F. Boyle | Original | Apr 8, 2019 |
| R-TX | Jodey C. Arrington | Original | Apr 8, 2019 |
| D-NJ | Jefferson Van Drew | May 1, 2019 | |
| D-MI | Elissa Slotkin | Oct 28, 2019 | |
| R-TX | Van Taylor | Oct 28, 2019 |
Committees 3
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Apr 8, 2019 |
| Health Subcommittee | Referred Apr 9, 2019Hearings May 21, 2019 | |
| House | Ways and Means Committee | Referred Apr 8, 2019 |
| Health Subcommittee | Referred Apr 8, 2019 | |
| Senate | Finance Committee | Referred Oct 29, 2019 |
Actions 14
Everything that happened, newest first.
- Oct 29, 2019Received in the Senate and Read twice and referred to the Committee on Finance.
- Oct 28, 2019Ms. Schakowsky moved to suspend the rules and pass the bill, as amended.
- Oct 28, 2019Considered under suspension of the rules. (consideration: CR H8516-8519)
- Oct 28, 2019DEBATE - The House proceeded with forty minutes of debate on H.R. 2115.
- Oct 28, 2019At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
In the Congressional Record 3
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| Extensions | Debate and remarks E1383 | Sheila Jackson Lee D-TX | Oct 31, 2019 |
| Extensions | Debate and remarks E1366 | Sheila Jackson Lee D-TX | Oct 29, 2019 |
| House | Debate and remarks H8516–H8519Text printed H8516Recorded votes H8520enact | Abigail Davis Spanberger D-VA, Earl L. "Buddy" Carter R-GA, Elissa Slotkin D-MI, Greg Gianforte R-MT, Janice D. Schakowsky D-IL, Jodey C. Arrington R-TX, Kurt Schrader D-OR, Michael C. Burgess R-TX | Oct 28, 2019 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 60, April 8, 2019, page H3129.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| Serial No. 116-37 | IMPROVING DRUG PRICING TRANSPARENCY AND LOWERING PRICES FOR AMERICAN CONSUMERS193 pages | Energy and Commerce Committee | May 21, 2019 |
CRS reports 1
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 1
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
Related bills 6
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 19 | Lower Costs, More Cures Act of 2019 | Related bill | Dec 19, 2019 |
| HR 2113 | Prescription Drug STAR Act | Related bill | Dec 24, 2020 |
| HR 2296 | More Efficient Tools to Realize Information for Consumers Act | Related bill | Sep 24, 2019 |
| S 3129 | Lower Costs, More Cures Act of 2019 | Related bill | Dec 19, 2019 |
| HR 3408 | Shop Rx Act of 2019 | Related bill | Jun 24, 2019 |
Titles 5
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend title XI of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers.
- Official Titles as Amended by House
- To amend titles XI and XVIII of the Social Security Act to provide greater transparency for discounts provided by manufacturers, to include real-time benefit information as part of a prescription drug plan's electronic prescription program under the Medicare program, and for other purposes.
- Short Title(s) as Introduced
- Public Disclosure of Drug Discounts Act
- Short Title(s) as Passed House
- Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
- Short Titles from RFS (Referred to Senate) bill text
- Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 3
Each version as it was printed, newest first.
- Oct 29, 2019Referred in Senate
- Oct 28, 2019Engrossed in House
- Apr 8, 2019Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
